Mike Hollan

Company executives detailed the company’s strategy for the coming year amidst a flurry of announcements.

David Ricks detailed how the company plans to build on the success of Zepbound and Lilly Direct.

CEO Rob Davis details specific funding forecasts for the company beyond Keytruda.

The company plans to expand its pipeline and be less reliant on a small number of blockbuster drugs.

As part of her continuing conversation with PharmExec, Trialynx CEO Angela Schwab goes into detail the importance of understanding a site’s abilities during the development stage of a trial.

CEO Christopher Boerner detailed the company’s plan to grow ahead of 2030.

Angela Schwab, founder and CEO of Trialynx, discusses the importance of designing trials around patients and how doing so doesn’t have to come at the cost of generating good data.

In the third part of her conversation with PharmExec, Trialynx founder and CEO Angela Schwab discusses the causes and solutions for high failure rates in clinical trials.

Trialynx founder and CEO Angela Schwab continues her conversation with PharmExec and explains the effective ways that AI is being used to tackle common problems with clinical trial design.

Angela Schwab, founder and CEO of Trialynx, discusses the current state of AI in the pharmaceutical industry and why it’s important for companies to demonstrate the true value of their AI-based products.

It’s unclear what direction the company will take based on how events unfolded after its last presentation.

If previous conference presentations are any indication, Merck will likely detail its plans to broaden its pipeline ahead of 2028.

The pharma giant will likely announce its acquisition plans for the coming year at the healthcare conference.

AbbVie has spent previous conferences detailing its work to rebuild its pipeline after losing Humira patent protection.

Pharmaceutical Executive detail’s the company’s history at the healthcare conference.

Ahead of the healthcare conference in January, Pharmaceutical Executive takes a look back at Novartis’ history at the conference.

The investment will allow the facility to meet the growing demand for RNAi therapeutics.

Nine more companies have joined the DTC government-run website, which is set to launch sometime next year.

The bill was part of the larger Defense Bill and will impact funding available to certain foreign companies.

The representatives from Pennsylvania and New York, joined with Democrats to force a vote on legislation against Speaker Johnson’s wishes.

In the third and final part of her conversation with Pharmaceutical Executive, discusses the ways that regulatory agencies in major global markets are acting in similar ways to have a positive impact on the biosimilars market.

Experts weigh in on FDA’s new accelerated review program, revealing what companies stand to benefit the most from the initiative.

Amid the US reshoring push, drugmakers navigate geopolitical and supply chain risks.

Will the politically fueled reforms and mandates around drug pricing reduce the complexity of the system?

The deal will provide Zealand with access to OTR’s proprietary R&D platform.

In the second part of her conversation with Pharmaceutical Executive, Gillian Woollett, VP and head of regulatory strategy at Samsung Bioepis, explains the direct impact changes at FDA have on the biosimilar space.

Gillian Woollett, VP and head of regulatory strategy at Samsung Bioepis, discusses how the current regulatory climate is the result of years of work.

The Lifescience Dynamics analyst discusses how GLP-1s appear to provide kidney protection in a specific, well-defined population.

In the final part of this conversation, Dr. Bruce Leuchter, CEO of Neurvati Neurosciences, discusses new programs at FDA and how the neuroscience space is benefitting.

Jay Bregman, co-founder of Andel, closes out our conversation by explaining the impact government programs will have on GLP-1 coverage.